The drug industry is already in the age of artificial intelligence

The health industry is going through a phase of structural transformation. Artificial Intelligence is no longer a theoretical horizon, but a concrete lever affecting research, development, production and quality control processes. It is in this context that the 65th AFI Symposium, the Association of Inudstry Pharmaceuticals scheduled to take place in Rimini from 10 to 12 June 2026, dedicated to the theme 'The Health Industry in the Time of Artificial Intelligence', fits in

The Symposium will represent the main national meeting point between companies, institutions and the scientific world. With more than 130 exhibiting companies already confirmed, the event will analyse the entire drug lifecycle: from the use of AI in the discovery of new molecules to the regulatory implications related to the European AI Act, which will be fully implemented in August 2026. Topics such as the use of Digital Twins in manufacturing processes, innovation in radiopharmaceuticals, the application of intelligent systems in quality control and the integration of the patient's voice in real-world evidence collection will be addressed. At the Symposium presentation last 24 February in Milan, we awarded the second edition of the Alessandro Rigamonti Prize, dedicated to the founder of AFI who passed away in 2024. Ten young researchers under 30, from Italian universities, were awarded for the originality and impact of their research.

The selected projects testify to the quality and concreteness of the new Italian scientific generation. These include the development of GlioGum, a biocompatible implant for local drug delivery in relapsing glioblastoma; molecularly imprinted 'trap' polymers for the management of gluten intake in coeliac disease; solvent-free polymeric micelles for oral drug delivery; lyophilised lipid nanoparticles for DNA delivery; and ultra-deformable liposomes obtained from sustainable biomass for controlled-release dermal applications. Other projects included a thermosensitive naloxone gel for needle-free jet injection in opioid overdose emergencies; redox-active nanogels for the prevention of cellular senescence and fibrosis; nanosystems targeted against Staphylococcus aureus in bone infections; studies on critical attributes for biosimilar approval; and 'green' deep eutectic solvents to improve stability and efficacy of delivery systems.

This research shows that innovation is not only digital, but scientific, formulation, regulatory and sustainable. Artificial Intelligence may amplify its impact, but the determining factor remains competence. The most recent data indicate a significant growth in AI adoption in Italian companies. However, we need to strengthen the culture of innovation and promote public-private partnerships so that this transition is truly sustainable and people-oriented. The 65th AFI Symposium in Rimini will be an opportunity to consolidate this path and to responsibly affirm the role of Italian industry in the new European technological scenario.

*President of the Associazione Farmaceutici Industria (AFI)